A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
Triple-negative breast cancer (TNBC) is one of the most aggressive and difficult to treat types of breast cancer. Here, a phase 2 clinical trial in TNBC patients reveals that the addition of lobaplatin to docetaxel and epirubicin regime improves pCR and ORR rates with tolerable side-effects.
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2018-02-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-018-03210-2 |